Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced that the company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for …